Skip to main content
. 2013 Nov 15;8(11):e80338. doi: 10.1371/journal.pone.0080338

Figure 3. Kaplan-Meier survival analysis of Beclin 1 expression in the testing set and the overall patient cohort.

Figure 3

(A) Low expression of Beclin 1 was closely correlated with poor overall survival and (B) progression-free survival in the testing set (n = 111). (C) Patients with lower Beclin 1 expression also acquired an inferior overall survival and (D) progression-free survival in the the overall patient cohort (n = 216). In the testing set and the overall patient cohort, the median duration of overall survival for patients with high and low expression of Beclin 1 was 108 VS. 24.5 months (p < 0.001) and 108 VS.28 months (p < 0.001), respectively.